Your shopping cart is currently empty

SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM) that recruits the MyD88 adaptor protein, activating downstream NF-κB and MAPK signaling pathways. In mouse models, SMU-L11 significantly enhances immune cell activation and boosts CD4+ T and CD8+ T cell proliferation, leading to direct tumor cell destruction and inhibition of tumor growth. This compound has applications in cancer research and potential in studying immune system disorders.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM) that recruits the MyD88 adaptor protein, activating downstream NF-κB and MAPK signaling pathways. In mouse models, SMU-L11 significantly enhances immune cell activation and boosts CD4+ T and CD8+ T cell proliferation, leading to direct tumor cell destruction and inhibition of tumor growth. This compound has applications in cancer research and potential in studying immune system disorders. |
| Targets&IC50 | TLR7:0.024 μM (EC50) |
| Formula | C19H24N4O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.